04 May

Alcyomics chooses BioPort to help with U.S. Market Entry Strategy

Alcyomics is a U.K. based biotech firm that offers human in vitro (lab-based) pre-clinical safety testing to ensure drug safety and efficacy before first administration into human beings. They have developed a one-of-a-kind preclinical safety testing protocol that will save pharmaceutical companies significant time and money. Some of the largest pharma companies in the world have called on the staff at Alcyomics to assist them when they have run into problems testing small molecule drugs.

“We have been called the problem solvers of the pharmaceutical industry because of your methods in determining what went wrong during pre-clinical trials,” says Annne Dicenson, founder and CEO of Alcyomics. Other markets that Alcyomics caters to include the chemical industry, and cosmetics industry where their assays have played an important role. BioPortUSA has been called upon to help develop and implement a strategic plan for new business opportunities in the USA.

“BioPortUSA is thrilled to be working with a company that has developed such cutting edge technology which can help companies predict a problem before it becomes one” said Mark Lesselroth, CEO of BioPortUSA. Over the coming months BioPort will deploy its expansive network to educate the pharmaceutical industry on the unique value proposition that Alcyomics has to offer.